Pharmaceuticals News and Research

RSS

SIS becomes an Industry Supporter of ASA

Surgical Information Systems (SIS) has become an Industry Supporter of the American Society of Anesthesiologists (ASA), as a part of a Corporate Supporter program available to pharmaceutical, medical device, anesthesia information management system and practice management companies.

29 Sep 2011

People with prehypertension have higher risk of experiencing future stroke

People with prehypertension have a 55 percent higher risk of experiencing a future stroke than people without prehypertension, report researchers at the University of California, San Diego School of Medicine in a new meta-analysis of scientific literature published in the September 28 online issue of the journal Neurology.

29 Sep 2011

TD2 wins AZBio's Fast Lane award for economic development of Arizona biosciences

TGen Drug Development (TD2) won a Fast Lane award from the Arizona BioIndustry Association (AZBio) for promoting the economic development of Arizona biosciences.

29 Sep 2011

Almirall submits linaclotide MAA to EMA for treatment of IBS-C

Ironwood Pharmaceuticals, Inc. today announced that its European partner Almirall, S.A. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation.

29 Sep 2011

Merck sells 50% interest in JJMCP joint venture

Merck, known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson & Johnson--Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson & Johnson (J&J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson & Johnson, Inc.

29 Sep 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

28 Sep 2011

Halozyme commences HTI-501 clinical trial for cellulite in women

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

28 Sep 2011

XECAN's RFID Oncology Solution integrated with ThingMagic Astra UHF Reader

Trimble announced today that m, a leading provider of RFID patient safety solutions, has integrated the ThingMagic Astra UHF Reader into its RFID Oncology Solution. The XECAN solution enhances the patient experience and significantly assists in the goal of eliminating treatment errors allowing healthcare organizations to offer a safer and more inviting medical experience.

28 Sep 2011

Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.

28 Sep 2011

HealthyWomen launches web-based initiative to manage RA

Managing RA: The Strong Woman's Approach, is an online resource designed to educate and empower women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org.

28 Sep 2011

U of A researchers discover active environmental catalyst

University of Alberta chemistry researchers have discovered an active catalyst that has the potential to improve the efficiency and environmental impact of manufacturing processes used to make products such as agrochemicals and pharmaceuticals.

28 Sep 2011

Survey shows rise in unprotected sex among youth, raises concern about sex education

"The number of young people having unprotected sex in the West has risen sharply over the past two years," according to a global survey conducted by the International Planned Parenthood Federation between April and May of this year, Agence France-Presse reports.

28 Sep 2011

Takeda, AACE partner to launch Diabetes Navigator website

The American Association of Clinical Endocrinologists (AACE) and Takeda Pharmaceuticals North America Inc. (Takeda) have partnered to launch the Diabetes Navigator, a compendium capturing a selection of useful and reliable type 2 diabetes information available online for patients and caregivers.

28 Sep 2011

UCI professor wins Presidential Early Career Award for Scientists & Engineers

Rommie Amaro, UC Irvine assistant professor of pharmaceutical sciences and computer science, has been selected by President Obama for the Presidential Early Career Award for Scientists & Engineers.

28 Sep 2011

Transcept announces resubmission of NDA for Intermezzo to FDA

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

CHRI second quarter revenues increase to $8 million

China Health Resource, Inc., a producer and supplier of Traditional Chinese Medicine (TCM) products, announced robust quarterly earnings for June 2011.

27 Sep 2011

Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical trial program will be presented in poster sessions at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society in Orlando, Florida.

27 Sep 2011

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory Society.

27 Sep 2011